MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Keros Therapeutics Cash and Cash Equivalents 2011-2026 | KROS
Annual Cash and Cash Equivalents Keros Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 560 M | 331 M | 279 M | 230 M | 266 M | 7.14 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 560 M | 7.14 M | 279 M |
Quarterly Cash and Cash Equivalents Keros Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 693 M | 690 M | 721 M | 560 M | 531 M | 406 M | 442 M | 331 M | 288 M | 322 M | 351 M | 279 M | 239 M | 216 M | 229 M | 230 M | 221 M | 237 M | 255 M | 266 M | 266 M | 266 M | 266 M | 7.02 M | 7.02 M | 7.02 M | 7.02 M | 23.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 721 M | 7.02 M | 298 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.29 | -1.98 % | $ 2.56 B |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.8 | -5.29 % | $ 4.36 M |  China |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 166.62 | 0.14 % | $ 8.29 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.45 | -3.26 % | $ 1.38 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
14.7 M | $ 25.77 | -4.06 % | $ 690 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
19.3 M | $ 0.97 | -5.15 % | $ 71.2 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
76.1 M | $ 3.15 | -5.69 % | $ 1.13 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
89.1 M | $ 28.45 | -2.57 % | $ 1.65 B | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 3.65 | -3.95 % | $ 116 M | France |
 |
Alector
ALEC
|
65.8 M | $ 2.1 | -5.2 % | $ 216 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
36.9 M | $ 4.16 | -0.12 % | $ 295 M | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
709 M | $ 23.99 | 0.46 % | $ 2.93 B | USA |
 |
Amarin Corporation plc
AMRN
|
135 M | $ 13.89 | -0.32 % | $ 5.76 B |  Irlanda |
 |
AbbVie
ABBV
|
5.23 B | $ 231.88 | -1.0 % | $ 410 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
102 M | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
27.1 M | $ 0.71 | -8.96 % | $ 34.1 M | USA |